← Back to screener

BIOMARIN PHARMACEUTICAL INC BMRN

Rank #1383 · Nasdaq · $11.3B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
49.1
P/E
67.5
P/B
2.46
ROE
3.6%
Op. Margin
7.7%
Debt Ratio
29%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 67.5x, P/B 2.46x. Ranks in the top 50% of the universe.

Profitability ★★☆☆☆
Average

ROE 3.6%. Ranks in the top 56% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 29%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Good

Revenue growth of 15.4% year over year. Ranks in the top 25% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.3B$0.0B$-0.0B$0.3B5.1197
2012$0.4B$0.0B$0.2B$0.3B0.1165
2013$0.4B$-0.0B$-0.1B$0.7B-7.777
2014$0.5B$-0.1B$-0.1B$0.8B-22.0117
2015$0.5B$-0.2B$-0.2B$1.0B-28.493
2016$0.7B$-0.1B$-0.1B$1.3B-12.499
2017$0.9B$-0.1B$-0.2B$1.5B-12.482
2018$1.1B$-0.8B$-0.6B$2.4B-71.976
2019$1.3B$-0.0B$-0.1B$2.8B-1.153
2020$1.5B$-0.1B$-0.1B$2.8B-8.356
2021$1.7B$-0.1B$-0.0B$3.0B-5.959
2022$1.9B$-0.0B$0.9B$3.1B-2.356
2023$1.8B$-0.1B$-0.1B$4.1B-4.543
2024$2.1B$0.2B$0.1B$4.3B7.744
2025$2.4B$0.2B$0.2B$4.6B7.729

← See the full screener